Business
Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight Therapeutics
Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight Therapeutics ...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nLeading Independent Proxy Advisory Firm ISS Recommends Change at Knight Therapeutics\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nPETACH TIKVA, Israel, April 25, 2019\n\n\n\nISS Notes \"Stark\" Underperformance, Recommends Election of New Independent Directors and for Knight Shareholders to Vote on the GOLD Proxy Card\nKnight's Third Largest Shareholder Publicly States its Support for All Medison Director Nominees\nMedison issues new profile videos of its director nominees at www.NewDayForKnight.com\n PETACH TIKVA, Israel, April 25, 2019 /CNW/ - Medison Biotech (1995) Ltd. (\"Medison\"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (\"Knight\" or the \"Company\"), today announced that Institutional Shareholder Services (\"ISS\"), a leading independent proxy advisory firm, has noted the \"stark\" underperformance of the Company and the need for change to the Knight Board of Directors.  ISS recommends that shareholders vote for change by using the GOLD proxy card.  In its reports, ISS recommends Knight shareholders vote FOR the election of Medison nominees Elaine Campbell and Christophe Robert Jean.  \nMedison agrees that significant change at the Board of Knight is needed to ensure that conflicts are removed, and skilled directors are put in place in order to build a sustainable pharma business and long-term value for its shareholders.  Medison is grateful for the publicly expressed support of Knight's third largest shareholder, Cambridge Global Asset Management, which has indicated that it intends to vote for all of Medison's director nominees.\n\"We appreciate the recommendation by ISS that change is needed at Knight,\" said Meir Jakobsohn, CEO of Medison, Knight's second largest shareholder.  \"Given the acknowledged conflicts between the CEO, the current Board and the Goodman family, in addition to the recognized underperformance of the company, we urge shareholders to support real change by voting FO...